An infection with the Zika virus (ZIKV) is usually mild, with nonspecific symptoms and most often asymptomatic. However, because of its causal relationship with severe congenital malformations, the ZIKV epidemic became an imperative for mobilization, renewed strategies for vector control, and biomedical research. A congenital Zika syndrome (CZS) has been characterized with 5 distinctive features that focus on brain development abnormalities (including microcephaly and brain calcifications), retinal manifestations, and defects on extremities including congenital contractures and hypertonia. The CZS could be just "the tip of the iceberg", pending the documentation of a spectrum of disease that could manifest later in life, from mild dysfunction to severe disease. It will be a matter of time for neurodevelopmental abnormalities, learning disabilities, and other unknown but yet-to-be-described outcomes to be associated with intrauterine ZIKV infection. In addition, ZIKV infection during pregnancy has been associated with other adverse outcomes. Reports mostly include ZIKV-affected pregnancies, and it will be difficult to clearly establish causality without appropriate control groups. We are summarizing some of the known or reported consequences of such infection during pregnancy. Women of reproductive age and particularly pregnant women are the most vulnerable to the adverse consequences of the ZIKV epidemic. Vector control programs need to be expanded to curtail new infections. Research is needed to develop safe and effective treatments, a preventive or therapeutic vaccine, and specific and sensitive tests and to diagnose and identify correlates of long-term immunity. Vaccines and treatments should be safe to be used in pregnancy. To do nothing would allow thousands of pregnant women to expose their fetuses to an infection that causes birth defects and other problems. Prenatal diagnosis technology development is necessary to be able to predict or diagnose adverse fetal outcomes related to ZIKV. Moreover, these tests should be used in a manner similar to the testing/screening method for neural tube defects and common chromosomal anomalies during prenatal care.
The treatments must be safe to be used in pregnancy, and the vaccine must be safe if we want to expedite the control of the exposure or the impact of the ZIKV infection during pregnancy. Vector control programs will need to be expanded to curtail new infections. To do nothing would allow thousands of pregnant women in many areas of the world to expose their fetuses to an infection that causes birth defects and other problems.
We are going to describe features of the Zika infection during pregnancy and the known fetal abnormalities associated with the ZIKV infection, called congenital Zika syndrome (CZS). In addition to fetal and infant severe manifestations, adverse pregnancy outcomes including fetal losses have been reported. Additional adverse outcomes have also been related to the infection during pregnancy. The information presented here is based on literature review including the following: case reports, case-control studies, retrospective and prospective cohort studies, and comprehensive reviews. The authors identify areas of research that could impact clinical monitoring and timely care of pregnant women and neonates.
usually a mild disease [3] [4] [5] . The disease is mild and self-limited, usually lasting 4-6 days. The most common signs and symptoms include pruritic rash, arthralgia, conjunctivitis, and low-grade fever [6] . A review of ZIKV in pregnancy by Lin et al [7] summarized the published maternal symptoms in order of frequency as follows: "maculopapular rash (sometimes pruritic) affecting 44%-93% of cases, followed by conjunctivitis (36%-58%), myalgia/arthralgia (39%-64%), headaches (53%-62%) and lymphadenopathy (about 40%)".
Of the 2 most severe manifestations of the ZIKV infection (microcephaly and GBS), it seems that pregnant women are more at risk of the former than the latter. Only 1 case of GBS in pregnancy has been reported [8] .
Pregnancy Complications
Early fetal losses (miscarriages) and intrauterine fetal demise (IUFD) have been described with more frequency in some cohorts of pregnant women with ZIKV infection. Fetal growth problems and placental-related dysfunctions have been reported among up to 20% of ZIKV-infected pregnancies even without observing fetal brain abnormalities on imaging studies [6, 9, 10] . In a preliminary report in Brazil in March 2016, researchers reported 2 miscarriages and 2 IUFD at 36 and 38 weeks among a cohort of 88 symptomatic pregnant women with ZIKV. When the numbers were expanded to 345 symptomatic women, 53% of whom tested positive for ZIKV, the rate of fetal losses was not different among both groups in the final report on December 2016 [6] . Intrauterine fetal demise and fetal hydrops were also reported in a pregnancy complicated by ZIKV infection with early intrauterine growth restriction (IUGR) from 18 weeks gestational age (GA), microcephaly, and brain calcifications identified by ultrasound (US) [10] .
Laboratory Diagnosis
The diagnostic aspects and challenges are covered elsewhere in this journal. However, we should mention that there are significant difficulties with diagnostic testing even in acute illness. Antibody testing confronts cross-reactivity with other vector-transmitted diseases such as dengue and chikungunya, which also share the same vector (Aedes aegypti).
In addition, accurate prenatal diagnosis of fetal infection is not yet available for ZIKV, and the testing might be inconclusive. The concerns with the potential risks of invasive procedures to obtain amniotic fluid samples limit its use. Some of the ZIKV-related adverse outcomes during pregnancy need time for the infection to cause fetal damage and therefore might be difficult to predict even with early testing.
Because of maternofetal communication and potential placental/fetal infection of the ZIKV, we expect maternal viremia to be more prolonged in some instances. Reports of prolonged viremia during pregnancy have documented as long as 89 days or 109 days after the onset of symptoms in serum samples of a pregnant Colombian woman in Spain [11] . Another case of prolonged viremia lasted for 70 days until the pregnancy was terminated [12] .
The Zika Virus Persistence Study evaluated 150 participants with confirmed ZIKV infection and reported persistence of viremia of >60 days among 4% (3 of 79) of the cohort. Among 5 pregnant women, 3 had viremia at 46 days after onset of symptoms and 80 days of persistence in 1 of them [13] .
Mysorekar and Diamond [14] proposed that based on mouse models and human cell and tissue samples, ZIKV could replicate in trophoblasts, fetal endothelial cells, and Hofbauer placental macrophages. Therefore, infection could be established in the placental site, causing severe placental vascular damage and a reduction in fetal blood vessels and blood flow. They further postulate that "ZIKV could cross the placental barrier and spread to the fetal brain, where it preferentially infects and injures neuronal progenitor cells" [14] . They further proposed that "Infection and death of neuro-progenitor cells could inhibit neuronal-cell differentiation, which would explain the cortical thinning, malformation of brain structures, and microcephaly that are observed during pregnancy in humans" [14, 15] .
If the ZIKV replicates either in any component of the fetoplacental unit, active replication would maintain and prolong maternal viremia and could explain the observation of prolonged positivity by reverse-transcription polymerase chain reaction (RT-PCR) in pregnancy, as mentioned in previous studies. The virus could establish infection in both compartments-fetal brain and placenta-and in theory could move from any of them to the maternal blood where it could be measured for a longer time than among nonpregnant individuals. At least 2 implications from these findings suggest a mechanism for fetal damage and the possibility of diagnosis of active ZIKV replication in pregnancy for a longer duration.
Ultrasound Evaluation and Diagnosis
A US evaluation of women infected in the first trimester demonstrated that (1) the earliest central nervous system (CNS) anomalies were detected at 19 weeks [12] and (2) identification of IUGR were detected at 18 weeks GA [10] . This finding means that there is a time window for the abnormalities to be identified after the initial infection, because the infection will take time for the neurologic damage to occur. Serial US evaluations will be able to identify abnormalities after they manifest and, in many cases, after the fetal viability age limiting interventions and pregnancy decisions.
The following are among the CNS abnormalities that can be identified by US: reduced growth velocity of the head circumference (HC), small/absent cavum septum pellucidum, asymmetrical cerebral hemispheres, partial/complete agenesis of the cerebellar vermis, microcalcifications, microcephaly, ventriculomegaly, hypoplastic cerebellum, and prominent choroid plexus [15] . Abnormal HC growth patterns among fetuses without neurologic manifestations with statistically significant lower HC among fetuses exposed to ZIKV after the 24th week have been reported. Ultrasound findings of 322 fetuses whose mothers had symptomatic ZIKV confirmed with ZIKV RT-PCR with no other findings suggestive of brain lesions were reviewed. The fetuses with normal brain imaging whose mothers were affected with ZIKV infection during pregnancy were observed to have smaller HC than controls (P = .0000154). The fetuses whose mothers were affected by ZIKV infection during pregnancy before 26 weeks of gestation without evidence of brain damage on sonography appear to have a normal growth pattern throughout the rest of the pregnancy. Zika virus infection after 26 weeks of gestation produced a tendency towards smaller HC (P = .0175), whereas other biometric parameters (abdominal circumference and femur length) were within the expected range (Albert De La Vega, MD, Oral communication, 2 February 2017). What are the implications or consequences of reduced fetal HC growth velocity? Would there be similar neurodevelopment among fetuses who demonstrated a lag in growth with later catch up? Evidently, there is a need for follow up of infants exposed to ZIKV in utero.
Causality
The causal relationship between prenatal ZIKV infection, microcephaly, and other serious brain anomalies has been documented by Rasmussen et al [16] . After reviewing the available evidence, and using Thomas Shepard 7 criteria to identify a human teratogen and the Bradford Hill criteria as framework, Rasmussen et al [16] suggested that there was sufficient evidence to infer a causal relationship between prenatal ZIKV infection, microcephaly, and other severe brain anomalies.
Other Perinatal Infections (TORCH)
Other perinatal infections are covered elsewhere in this issue. They are associated with 2%-3% of all congenital anomalies. TORCH is the acronym used to describe the most common vertical transmitted infections. TORCH refers to "toxoplasmosis, other (syphilis, varicella-zoster, parvovirus B19), rubella, cytomegalovirus (CMV), and herpes infections". These perinatal infections cause mild symptoms during pregnancy but might have severe fetal manifestations. The treatment of maternal infection when identified early might improve the fetal outcome for example with syphilis. Some of the infections have no treatment but could be prevented with vaccines (rubella), but the remainder present diagnostic challenges. Intrauterine infection can be suspected by abnormal US imaging, which include the following: microcephaly, cerebral calcifications, IUGR, ascites, and other manifestations in the case of CMV. Many infants are identified at birth. The fetus may be affected not only by the direct transmission of the agent but also indirectly by the consequences of maternal infection, such as preterm birth or IUGR. Zika virus infection might share similarities with congenital CMV, making proper diagnosis imperative.
Transmission Risks by Trimester of Exposure
The placenta can act as a barrier to infection because of its structure and function, but it can also have a role in infection transmission as previously stated. The embryo is most vulnerable to teratogenic during the early development from fertilization up to 10 weeks of GA. The period of organogenesis (18-60 days postconception in humans) is the most vulnerable time because it is the time when most structures are formed and might be vulnerable to teratogens [17] .
After the embryo is developed (during the fetal period), teratogens can cause cell death, retardation of cell growth, or inhibition of normal differentiation. Fetal growth restriction or CNS disorders might ensue. Early and serial US might facilitate the identification of such abnormalities. The rest of the fetal organs including the eyes, CNS, genital system, and hematopoietic systems continue to develop and are susceptible to damage by teratogens, including infectious agents [18] .
Driggers et al [12] reported for the first time the impact of the vertical transmission of the ZIKV and the clinical findings in the fetus. They also clearly documented the detection of ZIKV in the fetal brain, placenta, membranes, and umbilical cord. Zika virus infection may also induce an acute inflammatory response with up-regulation of interferons and cytokines and the indirect effect to the fetus [19] . Nowakowski et al [20] reported that the candidate viral entry receptor AXL is highly expressed by human radial glial cells, astrocytes, endothelial cells, and microglia in developing human cortex and by progenitor cells in developing retina. Even though maternal blood does not reach the placenta until the 10th week of gestation, an association between the risk of microcephaly and infection risk in the first trimester has been documented [21] .
Two reports of pregnancy outcomes after confirmed ZIKV infection during first, second, and third trimester showed rates of Zika-associated birth defects of 8%, 5%, and 4%, respectively, in United States territories [22] .
In previous studies in the United States, infection in the first trimester was associated with congenital birth defects in 11% of women with evidence of ZIKV infection. No birth defects were reported when infection occurred after the first trimester in that cohort [23] . Although the most severe brain abnormalities were seen in first-trimester infection, later infection during pregnancy has been also associated with adverse pregnancy outcomes and even postnatal microcephaly [6, 24] .
Both public health and individual concerns transcend the first 14 weeks of pregnancy (first trimester) and present a challenge to prevention because the risk to this infection (exposure) might last throughout pregnancy. Prevention strategies and avoidance of exposure need to persist for long periods of time. Safer sex practices have been recommended throughout pregnancy, and infected men should practice safe sex (condom use) for as long as 6 months [25] . Long-term behaviorial changes are needed to maintain consistent use of mosquito repellent, protective clothing, and avoidance of mosquito bites.
Transmission Risks by Maternal Symptomatology
We are not certain that symptomatic disease is associated with higher viral load and thus might present higher risk for transmission. Even with asymptomatic infection, pregnant women have congenital anomalies in a similar rate as symptomatic women. The rate of birth defects in the cohort in the United States was 6% among women with or without ZIKV symptoms [23, 26] . The rate of infection among the United States territories' cohorts was 7% among symptomatic women and 8% among asymptomatic women [22] .
Because the majority of the pregnancy outcomes have been reported retrospectively on women who presented with symptoms, we need prospective studies to determine ZIKV seroincidence and disease manifestations according to timing of infection and presence or absence of symptoms. It is evident that testing of pregnant women in affected areas will be needed to identify fetuses at risk for CZS and infants at risk of future neurodevelopmental problems. To that effect, the National Institutes of Health launched a prospective multicountry study to evaluate the magnitude of health risks that ZIKV infection poses to pregnant women and their developing fetuses and infants. The Zika in Infants and Pregnancy (ZIP) study will enroll 10 000 pregnant women to determine ZIKV seroconversion rates and maternal and fetal outcomes according to timing and type of infection [27] .
Estimating Risks of Microcephaly
The reported rate of microcephaly varied from 1 to 6 cases per 10 000 births in the United States [28] before this epidemic. As previously mentioned, the causal relationship between prenatal ZIKV infection and microcephaly and other serious brain anomalies has been documented [16] . The rate of first-trimester exposure of Zika-related microcephaly was estimated to be 1% (data from French Polynesia epidemic). This was estimate was later increased to 13% with modeling from the Brazil epidemic [29, 30] . Nevertheless, there has been some variation in the reported incidence of microcephaly among countries. The outcomes of more than 400 pregnancies from a registry of pregnant women with ZIKV infection in the United States and its territories confirmed and expanded the previous reports. The incidence of infants with birth defects among pregnant women with ZIKV infection was 6% for those presenting with or without symptoms any time during pregnancy. Moreover, the rate of birth defects among women exposed during the first trimester was 11% [23] .
The Brazilian cohort of symptomatic ZIKV-confirmed pregnant women (n = 72) reported a risk of any of the CZS features as 29% when the infection occurred in a wide range of GA (6-35 weeks) [6] . In contrast to the Brazil experience, Colombia has not reported such high incidence of CZS. Among a subgroup of 1850 pregnant women, more than 90% infected in the third trimester had delivered infants without abnormalities [31] . The reasons for these differences might include variations in population susceptibility due to prior yellow fever vaccination, prior dengue virus exposure, environmental or nutritional differences, or even Zika viral type.
Lin et al [7] suggests that the individual risk of CZS among infected women should be similar to that of the risk of other viral infections. "With maternal cytomegalovirus (CMV) infections, 30%-40% of fetuses become infected; of these, only about 12% develop signs and symptoms of congenital CMV syndrome [32] while the risk of congenital rubella syndrome with first-trimester maternal infection could be greater than 50%" [7, 33] . Aneuploidy screening and testing for fetal genetic disorders are currently recommended to all pregnant women in the United States (regardless of age) during prenatal care [34] .
These include antenatal screening for conditions such as Trisomy 21 or Down's syndrome that pose a risk of 1 in 800 live births in the United States. We argue that ZIKV screening/testing should be made available during pregnancy because the risk of CZS among those infected is approximately 50 times more frequent than the risk of aneuploidy (1 in 16 for CZS vs 1 in 800 live births for Trisomy 21). The CZV risk can fluctuate from 1% to 11%, as reported previously among women with ZIKV infection.
ZIKA AND NEONATES

Congenital Zika Syndrome: Definition and Pathogenesis
The CZS has been characterized with 5 distinctive features that focus on brain development abnormalities (including microcephaly and brain calcifications), ocular manifestations on the retina, and defects on extremities including congenital contractures and hypertonia [35] . The severe microcephaly seen in CZS is a more destructive process than that observed in many genetic forms of microcephaly, reflecting the massive neuronal cell death and necrosis. Severe microcephaly is defined as an HC below the third percentile for sex and age. Risk has been reported from 1% to 15% in confirmed prenatal Zika virus. The manifestations are predominantly neurologic with imaging showing cortical disorders, ventriculomegaly, hydrocephaly, cerebral calcifications, lissencephaly, periventricular, cortical and subcortical zones calcifications, cortical development errors, and pachygyria/agyria [20, 36, 37] . Neurological anomalies may be present in affected newborns with a normal HC. Affected infants can also present craniofacial disproportion. In addition to the evaluation for neurologic abnormalities including neuroimaging, a clinical assessment must include documentation of dysmorphic features, splenomegaly, hepatomegaly, and rash or other skin lesions.
Postnatal development of microcephaly was described among 13 infants born with normal-sized heads who later developed lag in fetal growth reaching the diagnostic criteria of microcephaly. Half of the mothers had symptoms between the second and fifth month, and all infants tested positive for ZIKV [24] . This observation is concerning, and it suggests that late infection might manifest postnatally due to the time needed for brain cells to manifest the damage. An infant with normal HC at birth cannot be excluded from the impact of intrauterine ZIKV infection. Pregnant women exposed to ZIKV infection cannot completely be reassured with a seemingly normal-sized infant. These postnatal severe manifestations reported in Brazil also indicate that the spectrum of disease (from normal to severe damage) might still present later as neurocognitive dysfunction.
The development of fetal brain and other congenital abnormalities are only one aspect of the impact of the Zika infection during pregnancy. Some have used the term "the tip of the iceberg" to implicate that this spectrum of disease will manifest later in life. It will be a matter of time before neurodevelopmental abnormalities, learning disabilities, and other unknown but yet-to-be described outcomes develop.
Neonatal Manifestations
Similar to other intrauterine-acquired infections, severity varies among infants. Infants with microcephaly have been diagnosed in utero with IUGR on US [10, [38] [39] [40] . They present with diverse ocular manifestations including the following: focal pigment mottling, cataracts, intraocular calcifications, chorioretinal macular atrophy, optic nerve abnormalities, conjunctival injections, optic disc cupping, microphthalmia, lens subluxation in addition to bilateral iris coloboma, foveal reflex loss, macular hypoplasia, and scarring [40] [41] [42] [43] .
Among the musculoskeletal abnormalities, clubfoot and severe arthrogryposis have been reported [15, 39] . Although the majority of these reports are related to abnormalities of infants born with microcephaly or severe CNS malformations, we expect that as time goes by and more infants are prospectively followed, subtle abnormalities in ocular, neuromuscular, and auditory systems will be observed. The same applies to neurodevelopmental milestones.
Neonatal Evaluations
Neonates with CZS need a comprehensive physical examination, including careful measurement of occipitofrontal circumference, length, weight, and assessment of GA. Zika virus infection can be diagnosed by a ZIKV ribonucleic acid nucleic acid test (NAT) or through serologic testing. It has not been established which test is most reliable for a diagnosis of congenital infection in newborns. Therefore, both tests are recommended. Cord blood use has been discouraged due to the possibility of maternal blood contamination. It is important that primary care providers continue to monitor the child's development and progress with standardized, validated developmental screening tools to ensure that the child's developmental needs are addressed [44] . Because infants with abnormal brain development can be at risk for hypothalamic dysfunction, which leads to pituitary insufficiency, thyroid screening should be performed at 2 weeks and at 3 months of age [44] . Because of the risk of sensorineural hearing loss and ocular manifestations, evoked oto-acoustic emissions testing or auditory brainstem response testing and ophthalmologic evaluation (including examination of the retina) should be performed either before discharge from the hospital or within 1 month after birth [45] .
Other clinical manifestations of CZS identified as risk factors for adverse neurodevelopmental outcomes include spasticity, seizures, irritability, and brainstem dysfunction including feeding difficulties. Longitudinal follow up is needed, especially for the infants admitted to neonatal intensive care units [46] .
Although all developmental screening tools are designed to identify children with potentially delayed development, each one approaches the task in a different way. There is no universally accepted screening tool appropriate for all populations and all ages [47] .
Preliminary data from Colombia and Panama also suggest that the genitourinary, cardiac, and digestive systems can be affected [21] . Further studies and consultation with pediatric subspecialists or clinical geneticist should be considered.
A Synchronized Approach to Prenatal, Pregnancy, and Neonatal Care: The
Role of Research
Research is needed on therapeutics for disease manifestations of ZIKV infection, to develop specific and sensitive tests and to identify correlates of long-term immunity. Prenatal diagnosis technology development is necessary to be able to predict or diagnose adverse fetal outcomes related to ZIKV infection. These tests should be used in a manner similar to the testing/ screening method for neural tube defects and chromosomal anomalies during prenatal care.
CONCLUSIONS
Women of reproductive age and particularly pregnant women are the most vulnerable to the adverse consequences of the ZIKV epidemic. This viral disease is asymptomatic in most individuals, and when symptomatic it presents a mild and self-limited illness, and it can produce devastating outcomes in pregnancy. The spectrum of disease for intrauterine-exposed infants range from normal to the most severe CZS and microcephaly. Infants might be born with normal-appearing features but might manifest neurodevelopmental delays and disabilities later in life. This is a new disease, and the world has seen only the early manifestations. It will be a matter of time for us to describe the mediumand long-term outcomes of those affected. The disease needs additional scientific studies to develop diagnostic methodologies, treatments, vaccines, vector control, and comprehensive care for those affected and impacted by the epidemic. The Zika epidemic is a public health challenge that will need close and intense efforts to curtail. Otherwise, a generation of individuals might have lifetime limitations due to a disability caused by a vector-transmitted infectious agent.
